MALVERN, PA — Uniquity Bio has named Will Kane as its new President and Chief Executive Officer, a move aimed at strengthening the company’s position as it advances its lead therapeutic candidate, solrikitug, through Phase II clinical trials and into anticipated Phase III development.
Kane, a veteran of the biopharmaceutical industry, brings more than 30 years of leadership experience across commercial and operational functions. He steps into the role following the departure of co-founder and former CEO Brian Lortie in June 2025. Kane most recently served as president and chief commercial officer at Anthos Therapeutics, which was recently acquired by Novartis. His resume also includes leadership positions at Karuna Therapeutics, BioXcel Therapeutics, Allergan, and Pfizer.
Uniquity Bio is advancing solrikitug, a monoclonal antibody targeting Thymic Stromal Lymphopoietin (TSLP), across multiple inflammatory indications. The drug candidate is currently being evaluated in three separate Phase II trials for asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). The company is positioning the therapy as a potential best-in-class treatment with improved dose flexibility and broader patient applicability.
“Will’s leadership, combined with his operational and commercial experience, are the right fit for Uniquity at this stage of the organization’s evolution and development,” said Bill Meury, chairman of the Uniquity Bio board of directors.
Board member Kiran Reddy, also a senior managing director at Blackstone Life Sciences, added that Kane’s appointment comes as the company enters a pivotal moment in its clinical and strategic growth. “Uniquity is in a strong position today — clinically, operationally and financially — and Will’s capabilities and expertise will help maximize the success of solrikitug,” said Reddy. He also credited outgoing CEO Brian Lortie for laying the groundwork that positioned the company for long-term impact.
Solrikitug works by blocking the interaction between TSLP and its receptors, a mechanism validated in treating a range of immunology and inflammation-driven diseases. In addition to its ongoing trials, Uniquity is also exploring bispecific antibodies combining solrikitug with other inflammatory targets to enhance efficacy and expand treatment reach.
“I am incredibly confident in the Uniquity Bio team and the potentially transformative impact of solrikitug as a highly potent and valuable anti-TSLP therapy,” Kane said in a statement. “Each step forward brings us closer to getting a much-needed medicine into the hands of millions of people suffering from underserved indications.”
Kane’s appointment signals Uniquity Bio’s intent to accelerate its path to commercialization, with eyes firmly set on delivering a novel solution in a crowded and competitive immunology landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.